

UNITED STATES DEPARTMENT OF COMMERCE

Pat nt and Trademark Offic Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

20

APPLICATION NO.	FILING DATE	FIRST NAMED INV	ENTOR		ATTORNEY DOCKET NO.
09/483,543	01/14/00	MUIR		T	600-1-259
- 023565 KLAUBER & JACKSON 411 HACKENSACK AVENUE		HM22/0329	7	EXAMINER	
			'	WEBER,	.J
HACKENSACK				ART UNIT	PAPER NUMBER
				1651	9
				DATE MAILED:	03/29/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trade k Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

		<u></u>	
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR /	ATTORNEY DOCKET NO.
ALL FIGHTION			
CONTROL NO.		PATENT IN REEXAMINATION	
CONTINUE NO.		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	<u> </u>

EXAMINER

ART UNIT

PAPER

9

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Applicant's election with traverse of Group I, claims 1-14 in Paper No. 8, filed 19 March 2001 is acknowledged. The traversal is on the ground(s) that the peptides of Group V and VII are specific examples within the scope of Group I. This is found persuasive and these claims will be rejoined with Group I. Claims 1-14, 33 and 50 will be considered on the merits. Claims 15-32 and 34-49 will be treated as if they had been non-elected without traverse because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement (MPEP § 818.03(a)) and are withdrawn from consideration.

The requirement is still deemed proper and is therefore made FINAL.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.


Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Jon P. Weber, Ph.D. Primary Examiner

Art Unit: 1651

Application No.: Of Applic

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE